XML 142 R69.htm IDEA: XBRL DOCUMENT
v3.22.1

Subsequent Events - Additional Information (Details) $ in Millions | Mar. 24, 2022 USD ($)
--- | ---
Subsequent Event | Affini-T Therapeutics, Inc. | Erasca Ventures |
Subsequent Event [Line Items] |
Amount invested for financing | $ 2.0

X
- Definition Amount of investment in equity security without readily determinable fair value. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 321 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714 + Details
Name: | us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event. + References No definition available. + Details
Name: | us-gaap_SubsequentEventLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=eras_AffiniTTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |